DRUG UTILIZATION REVIEW BOARD
January 20, 2010
205 JEFFERSON STREET
JEFFERSON CITY, MO 65101

Board Members Present
John Newcomer, M.D.
Peggy Wanner-Barjenbruch, M.D.
Charlene Heyde, R.Ph
Jennifer Passanise, F.N.P
Sandra Bollinger,Pharm.D.
Randy Beckner, Pharm.D,.
Susan Abdel-Rhaman, Pharm.D.

Committee Members Absent
David Campbell, M.D.
Joseph Yasso D,O.
Joy Gronstedt, D.O.
Sharad Parikh, M.D.
Stacy Mangum, Pharm.D

MO HealthNet Staff Present
George L. Oestreich, PharmD, Dep. Division Director
Rhonda Driver, R.Ph., Pharmacy Director
Jay Bryant-Wimp, RPh, Clinical Pharmacist
Andrew Haslag, Fiscal Manager
Tisha McGowan, Unit Supervisor
Mary Heet, R.N.
Allison Lauf, R.N.
D.J. Johnson, Program Development Spec.
Jackie Hickman, Unit Supervisor
Angela Wilson, Medicaid Specialist
Diana Jones, Director, Clinical Services
Jayne Zemmer, Program Manager
Carol Stock, Correspondence and Infromation Specialist
Jenna Twehus, RN
Beth McQuaide, Special Assistant

Contractors Present
Annette Walther, R.N., Infocrossing
Geri Roing, R.N., Infocrossing
Tom Beetem, R.Ph., Infocrossing
Pia Mosby, ACS Healthcare
Sophie Backes, Student Inter
Jennifer Kemp-Cornelius, Pharm.D, ACS Healthcare
Mark Roaseau, Pharm.D., M.D. ACS Healthcare
Rick Pope, Pharm.D.First Health Services
Courtney Iuppa, Student Intern

Others Attending
Don Frailey, GSK
Pam Sardo, Abbott
Randy McGinley, Bayer
Grant Cale, BMS
Diane Racicot, Strativa
Gina Luebbering, Budget and Planning
Debbie King, Amgen
Rod Woods, Medimmune
Steve Levinger, P&G
Marz Hagenhoff, Scicle
Ro b Kilo, Pfizer
Richard Mesquias, Lilly
Phil King, Pfizer
Martin Early, Schering Plough
Jake Knepp,
Bob Bollinger, Forest
Barbara Belcher, Merck
Todd Houldsworth, OMJ
Lon Lowry, Novartis
Chet Steckler, Purdue

Welcome, Introductions and Opening Remarks	John Newcomer, MD, Chairman called the meeting to order at approximately 10:00 a.m. Rhonda Driver, Director of Pharmacy introduced student interns, Sophie Backes, and Courtney Iuppa. Pia Mosby,a new ACS Helathcare staff member, was also welcomed.
Minutes Approval	Minutes from the October 21, 2009 meeting were approved with changes to the attendee list. (See Roll Call Vote)
Pharmacy Program Budget Update	George L. Oestreich, PharmD, Deputy Division Director discussed the overall state budget as well as the Pharmacy Program budget. He sated the Pharmacy year started very strong, with significant MAC Pricing savings being seen. Jay Bryant-Wimp provided a summary on the implementation of the Specialty MAC pricing edit. Several tough years are being projected. He noted that the Department and Division are continuing to look for overall savings opportunities. The Pharmacy program will continue with the efforts in place and look at additional opportunities to use the tools in place as well as ways to implement edits more quickly. Appreciation for the assistance the Board provides was given. Dr. Oestreich summarized the ongoing Lewin Review; preliminary information from Lewin will be released next month. Chronic Care Program successes are under review and clinical outcomes look to be very good. It is hoped fiscal outcomes will be promising as well. Discussion ensued regarding the Managed Care Carve out to Fee-for-Service which has fairly seamless. Pharmacy staff are responding to question coming in from providers needing clarification for specific medication coverage. Dr. Oestreich touched on the recent change from AWP pricing. MO HealthNet had not used AWP for several years amd the Division expects no impact from this change. He clarified the pricing formula use by the program in response to a question from the audience. No slides were presented due to the large agenda to be covered.
Review Of Prior Authorization Meeting and Public Hearing	The Drug Prior Authorization Committee met and held the public hearing, for MHD recommendations for edits under review during this quarter, on September 1, 2009. A complete Drug PA meeting packet was included with meeting handouts to the DUR Board for review and action and to all attendees. Each document and the discussion surrounding is detailed below. A copy of the draft minutes from the Drug PA Committee was included for the Board members information as well.
Old Business	
Triptan PDL Edit	●Discussion-A copy of the clinical edit document was provided in the meeting packet and all attendees. Changes under recommendation were bolded for easy identification. Ms. Driver reviewed the document noting the compliance model for the class was now defined as therapy 15 days out of the most recent 60 days. This change had been discussed and recommended at the previous meetings of the Drug Prior Authorization Committee and DUR Board. ● Decision-In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)

Megace ES	● A copy of the clinical edit document was provided in the meeting packet and all attendees. Ms. Driver explained at the request of the manufacturer of the product Megace ES a review of the existing Megestrol Acetate Clinical Edit was conducted. MHD was recommending the addition of Megace ES, currently under prior authorization, to the current Megestrol Acetate clinical edit. ●Public Hearing-Diane Ranicot, Strativa Pharmaceuticals addressed the Committee requesting Megace ES be removed from the clinical edit. She discussed the differences between Megace ES and Megace. Dr, Ranicot stated benefits of Megace ES included improved bio-availability in unfed patients, lower volume dose, and a viscosity of 94% less than the original formulation Megace. Dr. Ranicot noted an error under denial criteria in the document. The document will be corrected to indicate recommend dose to not exceed 800 mg per day for the product. Dr. Ranicot indicated the product was only meant to be used for at 90 day period. ●Decision- After Committee discussion the vote was tabled to allow for review of duration of therapy data. ● Decision-In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Implementation Schedule	An updated copy of the *Proposed Implementation Schedule for Edits* was included in the members' meeting packet and as a handout to all attendees. The schedule had been updated with all edits approved at the last quarter's meeting. This included the implementation following the annual review of half of the PDL done in March and April and implemented in July. The schedule may be found on the MHD Web-site at http://dss.missouri.gov/mhd/cs/pharmacy/imsched.pdf.
New Business	
New Drug Review	● Discussion- Drug monographs for products reviewed during this quarter were available at http://www.heritage-info.com/mohealthnet. A listing of products detailing MHD's recommendations for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all in attendance. ● Decision-In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
PDL Edits	The classes reviewed this quarter were new additions to the Preferred Drug List (PDL).
Fibromyalgia Agents	● Discussion – Ms. Driver reviewed the criteria document provided as a meeting handout. Preferred and Non Preferred agents as well as existing clinical edits that will continue as the products are rolled into the PDL were summarized. ● Public Hearing – Phil King, Pfizer Pharmaceuticals requested the Committee consider the

	product Lyrica be move to preferred status. Dr. King discussed the differences of the product, clinical studies, safety, and efficacy of the product. ● Decision – The Committee voted to accept the recommendation as presented. (See Roll Call Votes)
Cryopyrin-Associated Periodic Syndrom (CVAPS(Agents	● Discussion – Mr. Bryant-Wimp reviewed the criteria document, noting preferred and non-preferred agents and approval/denial criteria. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept the recommendation as presented. (See Roll Call Votes)
Self Injectable Epinephrine Agents	● Discussion – Ms. Driver reviewed the criteria document provided as a meeting handout noting MHD recommendations for preferred and non-preferred agents. Questions from the Committee surrounding the non preferred agent were answered. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept the recommendation as presented. (See Roll Call Votes)
Tramadol Like Agents	● Discussion – Mr. Bryant-Wimp reviewed the criteria document noting recommendations for preferred and non-preferred agents. Approval and denial criteria were reviewed as well. Discussion ensued surrounding serotonin syndrome. The Committee concurred that this would be an excellent topic for a DUR newsletter. ● Public Hearing – Brian Macomson, Johnson and Johnson discussed the product Nucynta and requested preferred status be considered. The differences of the product, clinical trials, safety and efficacy data were presented, ● Decision –The Committee voted to accept the recommendation as presented. (See Roll Call Votes)
Pulmonary Hypertension Agents	● Discussion – Mr. Bryant-Wimp reviewed the criteria document noting recommendations for preferred and non-preferred agents. A clarification that this edit was for inhaled and inject-able agents (Oral agents are already part of the PDL) was given by Ms. Driver. She indicated the two dosing forms would be merged into one edit in the future. ● Public Hearing – No comments were entered. ● Decision –The Committee voted to accept the recommendation as presented, however wish to review utilization data as warranted.. (See Roll Call Votes)
Preferred Drug List Announcement	A handout of therapeutic categories for review and inclusion in the PDL during the next quarter was included in the meeting packet and to all meeting attendees. This listing will be posted to the Division's Web page at http://www.dss.mo.gov.mhd. The posting will also be updated with the MHD recommendations prior to the December Drug Prior Authorization Committee meeting.
ACS HealthCare Update	Jennifer Kemp-Cornelius, PharmD. ACS Healthcare Systems summarized the current clinical edit for ADHD therapy. Slides shared provided preliminary claim and paid amounts graphs for

	children under six years of age. Helpdesk approval/denial statistics were also shared. Dr. Kemp-Cornelius explained at each Drug Utilization Review Board meeting she would like to pick an edit that is not routinely reviewed each year as she reviewed each of the documents.
Program Utilization Information Top 25 Report	A listing of the top 25 drugs for dates of services between January 2007 and third quarter 2008 was provided for the Boards' Information. This report was provided in two formats: ranked by number of claims and ranked by amount paid. Copies were available to all attendees.
Clinical Edit Summary Report	An overview of clinical edit and prior authorization transactions was provided for the month of September 2009. The report provided total transaction counts as well as information on the outcome (approval or denial) of the request. CyberAccess[SM] log in information for the months of April 2006 through September 2009 was provided for the members review as well. Dr. Cornelius summarized these statistics including total log ins to each of the available applications. The report included active user counts as well.
Other Business/Adjourn	The next meeting of the Board is scheduled for January 20, 2010. The Drug Utilization Review Board went into executive session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See Roll Call Vote)

ROLL CALL VOTES

MEMBER	MINUTES	PA RECOMNEDATIONS	TRIPTANS	CLOSED SESSOIN	ADJOURN
John Newcomer	Yeah	Yeah	Motion	Yeah	Yeah
Susan Abdel-Rahman	Yeah	Yeah	Yeah	Yeah	Yeah
Peggy Wanner-Bargenbruch	Yeah	Second	Second	Yeah	Yeah
Randy Beckner	Yeah	* see below	*see below	Motion	Yeah
Sandra Bollinger	Motion	Yeah	Yeah	Yeah	Yeah
David Campbell	Absent	Absent	Absent	Absent	Absent
Joy Gronstedt	Absent	Absent	Absent	Absent	Absent
Charlene Heyde	Second	Yeah	Yeah	Yeah	Second
Stacy Mangum	Absent	Absent	Absent	Absent	Absent
Sharad Parikh	Absent	Absent	Absent	Absent	Absent
Jennifer Passanise	Second	Motion	Yeah	Second	Motion
Joasph Yasso	Absent	Absent	Absent	Absent	Absent

* Dr. Beckner excused himself from the votes on the following classes: Oral Anti-diabetics, Bone Ossification Suppression Agents, Urinary Tract Antispasmodics, Intra-nasal Steroids, Triptans, TZD's and Herpes Antiviral Agents. All other PDL class votes were recorded as Yeah.

Executive Session
01/20/2010

John Newcomer, M.D.
Peggy Wanner-Barjenbruch, M.D.
Charlene Heyde, R.Ph
Jennifer Passanise, F.N.P
Sandra Bollinger,Pharm.D.
Randy Beckner, Pharm.D,.
Susan Abdel-Rhaman, Pharm.D.

Committee Members Absent
David Campbell, M.D.
Joseph Yasso D,O.
Joy Gronstedt, D.O.
Sharad Parikh, M.D.
Stacy Mangum, Pharm.D

George L. Oestreich, PharmD, Dep. Division Director
Rhonda Driver, R.Ph., Pharmacy Director
Jay Bryant-Wimp, RPh, Clinical Pharmacist
Andrew Haslag, Fiscal Manager
Tisha McGowan, Unit Supervisor
Mary Heet, R.N.
Allison Lauf, R.N.
Jenna Twehus, RN
Beth McQuaide, Special Assistant

Contractors Present
Jennifer Kemp-Cornelius, Pharm.D, ACS Healthcare
Mark Roaseau, Pharm.D., M.D. ACS Healthcare
Rick Pope, Pharm.D.First Health Services

Minutes Review and Approval	Minutes were approved as submitted
Case reviews	Jenna Twehus, RN presented a patient profile for review and recommendation by the Board. Ms Twehus summarized the profile for a 50 year old female being treated with current pain therapy which included Oxycontin 80 mg #630/30days, Fentanyl Cit OTFC 1600 mcg/30 day and up to date MHD discussion with treating physician. The Board made recommendations which included referral for a pain pump.